INTRODUCTION: First-line chemotherapy (CT1) is effective in advanced biliary tract cancer (ABTC). The benefits of second-line chemotherapy (CT2) are unclear. METHODS: We retrospectively studied all patients starting at least one line of chemotherapy for ABTC at our institution between 1991 and 2011. We analysed patient and chemotherapy characteristics in order to: (1) characterise patients eligible for CT2; (2) evaluate the efficacy of CT2. RESULTS: Three hundred and seventy-eight received CT1 and 96 (25%) patients received CT2. Primary tumour location was the gallbladder (29%), intraphepatic (20%), perihilar (16%), distal common bile duct (19%) and ampulla of Vater (14%). Ninety percent had a baseline performance status (PS) of 0-1 prior to CT1. Females (p=0.03), ages ≤ 60 years (p=0.001) and patients with progression free survival (PFS) ≥ 6 months following CT1 (p=0.01) were more likely to be offered CT2. Objective response rates and stable disease with CT2 were 9% and 34%, respectively. Median PFS and median overall survival (OS) from the beginning of CT2 were 2.8 and 7.5 months, respectively. Prognostic factors impacting PFS with CT2 were the regimen type (doublet versus monotherapy, p=0.001) and PS<2 (p<0.0001). CONCLUSIONS: Among patients with ABTC, 25% received CT2, typically younger patients and those with longer PFS following CT1. Disease control occurred in 43% of patients, and more often with a doublet than a single agent. However, clearly more effective therapies must be found. Crown
INTRODUCTION: First-line chemotherapy (CT1) is effective in advanced biliary tract cancer (ABTC). The benefits of second-line chemotherapy (CT2) are unclear. METHODS: We retrospectively studied all patients starting at least one line of chemotherapy for ABTC at our institution between 1991 and 2011. We analysed patient and chemotherapy characteristics in order to: (1) characterise patients eligible for CT2; (2) evaluate the efficacy of CT2. RESULTS: Three hundred and seventy-eight received CT1 and 96 (25%) patients received CT2. Primary tumour location was the gallbladder (29%), intraphepatic (20%), perihilar (16%), distal common bile duct (19%) and ampulla of Vater (14%). Ninety percent had a baseline performance status (PS) of 0-1 prior to CT1. Females (p=0.03), ages ≤ 60 years (p=0.001) and patients with progression free survival (PFS) ≥ 6 months following CT1 (p=0.01) were more likely to be offered CT2. Objective response rates and stable disease with CT2 were 9% and 34%, respectively. Median PFS and median overall survival (OS) from the beginning of CT2 were 2.8 and 7.5 months, respectively. Prognostic factors impacting PFS with CT2 were the regimen type (doublet versus monotherapy, p=0.001) and PS<2 (p<0.0001). CONCLUSIONS: Among patients with ABTC, 25% received CT2, typically younger patients and those with longer PFS following CT1. Disease control occurred in 43% of patients, and more often with a doublet than a single agent. However, clearly more effective therapies must be found. Crown
Authors: Lipika Goyal; Hui Zheng; Matthew B Yurgelun; Thomas A Abrams; Jill N Allen; James M Cleary; Michelle Knowles; Eileen Regan; Amanda Reardon; Anna Khachatryan; Rakesh K Jain; Valentina Nardi; Darrell R Borger; Dan G Duda; Andrew X Zhu Journal: Cancer Date: 2017-02-13 Impact factor: 6.860
Authors: Changqing Xie; Austin G Duffy; Donna Mabry-Hrones; Bradford Wood; Elliot Levy; Venkatesh Krishnasamy; Javed Khan; Jun S Wei; David Agdashian; Manoj Tyagi; Vineela Gangalapudi; Suzanne Fioravanti; Melissa Walker; Victoria Anderson; David Venzon; William D Figg; Milan Sandhu; David E Kleiner; Maria Pia Morelli; Charalampos S Floudas; Gagandeep Brar; Seth M Steinberg; Firouzeh Korangy; Tim F Greten Journal: Hepatology Date: 2019-03-10 Impact factor: 17.425
Authors: Mark K Doherty; Mairéad G McNamara; Priya Aneja; Emma McInerney; Stephanie Moignard; Anne M Horgan; Haiyan Jiang; Tony Panzarella; Raymond Jang; Neesha Dhani; David Hedley; Jennifer J Knox Journal: J Gastrointest Oncol Date: 2017-04
Authors: Mairéad G McNamara; John Bridgewater; Daniel H Palmer; Olusola Faluyi; Harpreet Wasan; Alkesh Patel; William D Ryder; Safia Barber; Chathunissa Gnanaranjan; Essam Ghazaly; T R Jeff Evans; Juan W Valle Journal: Oncologist Date: 2020-12-03
Authors: Matthias Unseld; Werner Scheithauer; Roman Weigl; Gabriela Kornek; Nadja Stranzl; Daniela Bianconi; Georg Brunauer; Guenther Steger; Christoph C Zielinski; Gerald W Prager Journal: J Gastrointest Oncol Date: 2016-08
Authors: M Sinn; A Nicolaou; B Gebauer; P Podrabsky; D Seehofer; J Ricke; B Dörken; H Riess; B Hildebrandt Journal: Dig Dis Sci Date: 2013-03-24 Impact factor: 3.199